Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure. This technology may offer an alternative to traditional microfracture and complex cell-based therapies, addressing a significant unmet need in orthopedics.
The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. These results position GelrinC as a potential game-changer in the field.
GelrinC has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission. The company’s platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone.
The importance of this advancement lies in the simplicity and accessibility of the treatment. Unlike existing therapies that require multiple surgeries or cell harvesting, GelrinC is an off-the-shelf product that can be implanted in a single procedure. This could significantly reduce recovery times and healthcare costs while improving patient outcomes.
For more information, see the full corporate profile at https://ibn.fm/bpPp6. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.